Olle Ringdén Research Group

Allogeneic Hematopoietic Stem Cell Transplantation: Research Profile

  1. With genomic and immunological techniques predict patients at risk of severe graft-versus-host disease (GVHD).
  2. Optimally use the antileukemic effect by GVHD.
  3. Improve immune reconstitution after allogeneic hematopoietic stem cell transplantation (HSCT) by the development of cytotoxic T-cells (CTL) against Epstein-Barr virus, cytomegalovirus, adenovirus and aspergillus.
  4. Expand T-cells from cord blood transplants to be used for immunotherapy.
  5. Develop the graft-versus-cancer effect in solid tumors, such as prostate cancer, pancreas carcinoma, colon carcinoma, renal carcinoma and liver carcinoma. Develop CTL against prostate as immunotherapy in prostate cancer.
  6. Culture and expand stromal cells from different tissues like placenta and study alloreactivity in vitro. Study mechanisms. Use stromal cells for treatment and prevention of GVHD in prospective studies.

The Olle Ringdén Research Group and Laboratories are located within the Karolinska University Hospital Huddinge, Division of Clinical Immunology F71-79 and CAST B87.

Group Members

Group Leader Professor Olle Ringdén

Phone:
+46 (0) 585 826 72
E-mail:
Address:
  • Karolinska Institutet
    Division of Clinical Immunology
    Karolinska University Hospital Huddinge F79
    S-141 86 Stockholm

Secretary Inger Hammarberg

Phone:
+46 (0)8 5858 1388
E-mail:
Address:
  • Karolinska Institutet
    Division of Clinical Immunology
    Karolinska University Hospital Huddinge F79
    S-141 86 Stockholm

Senior Researcher Mehmet Uzunel

E-mail:
Address:
  • Karolinska Institutet
    Division of Clinical Immunology
    Karolinska University Hospital Huddinge F79
    S-141 86 Stockholm

Senior Researcher Helen Karlsson

E-mail:
Address:
  • Karolinska Institutet
    Division of Clinical Immunology
    Karolinska University Hospital Huddinge F79
    S-141 86 Stockholm

Bio Medical Analyst Silvia Nava

E-mail:
Address:
  • Karolinska Institutet
    Division of Clinical Immunology
    Karolinska University Hospital Huddinge F79
    S-141 86 Stockholm

MD, PhD Brigitta Omazic

Phone:
+46 (0)8 5858 0000
E-mail:
Address:
  • Karolinska Institutet
    Division of Clinical Immunology
    Karolinska University Hospital Huddinge F79
    S-141 86 Stockholm

Postdoc Richard Olsson

Phone:
+46 (0)8 5858 0000
E-mail:
Address:
  • Karolinska Institutet
    Division of Clinical Immunology
    Karolinska University Hospital Huddinge F79
    S-141 86 Stockholm

PhD Student Nicholas Karlsson

Phone:
+46 (0)8 5858 0000
E-mail:
Address:
  • Karolinska Institutet
    Division of Clinical Immunology
    Karolinska University Hospital Huddinge F79
    S-141 86 Stockholm

PhD Student Tom Erkers

Phone:
+46 (0)8 5858 0000
E-mail:
Address:
  • Karolinska Institutet
    Division of Clinical Immunology
    Karolinska University Hospital Huddinge F79
    S-141 86 Stockholm

Selected publications

Karlsson H, Nava S, Remberger M, Hassan Z, Hassan M, Ringden O

N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell mediated immunity in vitro.

European Journal of Immunology 41:1143-1153, 2011.

Ringdén O, Hassan Z, Karlsson H, Olsson R, Omazic B, Mattsson J, Remberger M.

Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease.

Transplantation 90:1022-1029, 2010.

Uhlin M, Okas M, Karlsson H, Gertow J, Henningsohn L, Ringdén O, Kärre K, Levitsky V, Mattsson J.

Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoietic stem-cell transplantation.

Transplantation 87: 467-472, 2009.

Ringdén O, Pavletic S, Anasetti C, Barrett JA, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks D, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, Scouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM, Arora M.

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

Blood 113:3110-3118, 2009.

Karlsson H, Samarasinghe S, Ball L, Sundberg B, Lankester AC, Dazzi F, Uzunel M, Veys P, Le Blanc K, Ringdén O, Amrolia P.

Mesenchymal stem cells exert differential effects on alloantigen- and virus-specific T-cell responses.

Blood 112: 532-541, 2008.

Last modified by: Naradja Wissmar 2011-09-15